Vivos Therapeutics, Inc.
VVOS
$0.53
-$0.04-7.12%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 70.46% | 3.41% | 75.73% | -5.77% | -11.79% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 70.46% | 3.41% | 75.73% | -5.77% | -11.79% |
| Cost of Revenue | 38.16% | -47.78% | 86.50% | 21.88% | 1.69% |
| Gross Profit | 102.72% | 42.49% | 68.68% | -20.41% | -22.10% |
| SG&A Expenses | 75.62% | 87.60% | 71.47% | 50.14% | -5.85% |
| Depreciation & Amortization | 156.50% | 206.94% | 163.01% | 111.03% | 21.23% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 69.54% | 56.92% | 77.05% | 44.99% | -3.75% |
| Operating Income | -68.84% | -127.44% | -78.98% | -151.29% | -3.51% |
| Income Before Tax | -100.60% | -145.99% | -106.42% | -159.74% | -2.68% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -100.60% | -145.99% | -106.42% | -159.74% | -2.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -98.81% | -143.86% | -106.42% | -159.74% | -2.68% |
| EBIT | -68.84% | -127.44% | -78.98% | -151.29% | -3.51% |
| EBITDA | -64.69% | -123.14% | -74.07% | -154.55% | -2.80% |
| EPS Basic | -16.77% | -41.95% | -24.56% | 7.71% | 72.43% |
| Normalized Basic EPS | -16.12% | -41.22% | -24.51% | 7.71% | 72.42% |
| EPS Diluted | -16.77% | -41.95% | -24.56% | 7.71% | 72.43% |
| Normalized Diluted EPS | -16.12% | -41.22% | -24.51% | 7.71% | 72.42% |
| Average Basic Shares Outstanding | 70.26% | 71.76% | 65.73% | 181.48% | 272.38% |
| Average Diluted Shares Outstanding | 70.26% | 71.76% | 65.73% | 181.48% | 272.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |